SpringerLink
Log in

Epidemiology, Presentation, and Evaluation

  • Chapter
  • First Online:
Neuroblastoma

Part of the book series: Pediatric Oncology ((PEDIATRICO))

  • 70 Accesses

Abstract

Neuroblastoma is the most common extracranial solid tumor of childhood and the most common malignancy of infancy. Primary tumors most commonly arise in the adrenal gland or along the sympathetic ganglion chain in the chest, abdomen, or pelvis. Presenting symptoms generally correspond to the site of the primary tumor, though patients with metastatic disease may present with constitutional symptoms as well. Common sites of metastatic disease include lymph nodes, bone marrow, and cortical bone. Treatment for children with neuroblastoma is determined based on risk for disease recurrence, as assessed by evaluation of clinical and tumor biologic factors. Current factors used in risk assessment include clinical stage, patient age at diagnosis, tumor histology, tumor MYCN amplification status, tumor segmental chromosomal aberration status, and tumor cell ploidy. Response to therapy is assessed using the revised International Neuroblastoma Response Criteria.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (Brazil)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (Brazil)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 179.99
Price excludes VAT (Brazil)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975-2014. Bethesda: National Cancer Institute; 2017.

    Google Scholar 

  2. London WB, Castleberry RP, Matthay KK, et al. Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children’s Oncology Group. J Clin Oncol. 2005;23(27):6459–65.

    Article  CAS  PubMed  Google Scholar 

  3. Esiashvili N, Goodman M, Ward K, Marcus RB Jr, Johnstone PA. Neuroblastoma in adults: incidence and survival analysis based on SEER data. Pediatr Blood Cancer. 2007;49(1):41–6.

    Article  PubMed  Google Scholar 

  4. Brodeur G, Hogarty MD, Bagatell R, Mosse YP, Maris JM. Neuroblastoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. 7th ed. Alphen aan den Rijn: Wolters Kluwer; 2015. p. 772–97.

    Google Scholar 

  5. Mosse YP, Deyell RJ, Berthold F, et al. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer. 2014;61(4):627–35.

    Article  PubMed  Google Scholar 

  6. Bluhm EC, Daniels J, Pollock BH, Olshan AF, Children’s Oncology Group. Maternal use of recreational drugs and neuroblastoma in offspring: a report from the Children’s Oncology Group (United States). Cancer Causes Control. 2006;17(5):663–9.

    Article  PubMed  Google Scholar 

  7. Chow EJ, Friedman DL, Mueller BA. Maternal and perinatal characteristics in relation to neuroblastoma. Cancer. 2007;109(5):983–92.

    Article  PubMed  Google Scholar 

  8. Cook MN, Olshan AF, Guess HA, et al. Maternal medication use and neuroblastoma in offspring. Am J Epidemiol. 2004;159(8):721–31.

    Article  PubMed  Google Scholar 

  9. De Roos AJ, Teschke K, Savitz DA, et al. Parental occupational exposures to electromagnetic fields and radiation and the incidence of neuroblastoma in offspring. Epidemiology. 2001;12(5):508–17.

    Article  PubMed  Google Scholar 

  10. Heck JE, Ritz B, Hung RJ, Hashibe M, Boffetta P. The epidemiology of neuroblastoma: a review. Paediatr Perinat Epidemiol. 2009;23(2):125–43.

    Article  PubMed  Google Scholar 

  11. McCall EE, Olshan AF, Daniels JL. Maternal hair dye use and risk of neuroblastoma in offspring. Cancer Causes Control. 2005;16(6):743–8.

    Article  PubMed  Google Scholar 

  12. Olshan AF, De Roos AJ, Teschke K, et al. Neuroblastoma and parental occupation. Cancer Causes Control. 1999;10(6):539–49.

    Article  CAS  PubMed  Google Scholar 

  13. Olshan AF, Smith J, Cook MN, et al. Hormone and fertility drug use and the risk of neuroblastoma: a report from the Children’s Cancer Group and the Pediatric Oncology Group. Am J Epidemiol. 1999;150(9):930–8.

    Article  CAS  PubMed  Google Scholar 

  14. Trochet D, O’Brien LM, Gozal D, et al. PHOX2B genotype allows for prediction of tumor risk in congenital central hypoventilation syndrome. Am J Hum Genet. 2005;76(3):421–6.

    Google Scholar 

  15. Pattyn A, Morin X, Cremer H, Goridis C, Brunet JF. The homeobox gene Phox2b is essential for the development of autonomic neural crest derivatives. Nature. 1999;399(6734):366–70.

    Article  CAS  PubMed  Google Scholar 

  16. Trochet D, Bourdeaut F, Janoueix-Lerosey I, et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet. 2004;74(4):761–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. van Limpt V, Schramm A, van Lakeman A, et al. The Phox2B homeobox gene is mutated in sporadic neuroblastomas. Oncogene. 2004;23(57):9280–8.

    Article  PubMed  Google Scholar 

  18. Di Lascio S, Benfante R, Di Zanni E, et al. Structural and functional differences in phox2b frameshift mutations underlie isolated or syndromic congenital central hypoventilation syndrome. Hum Mutat. 2017;39(2):219–36.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Berdon WE, Stylianos S, Ruzal-Shapiro C, Hoffer F, Cohen M. Neuroblastoma arising from the organ of Zuckerkandl: an unusual site with a favorable biologic outcome. Pediatr Radiol. 1999;29(7):497–502.

    Article  CAS  PubMed  Google Scholar 

  20. Vo KT, Matthay KK, Neuhaus J, et al. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project. J Clin Oncol. 2014;32(28):3169–76.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Dinh T, Truong B, Matthay KK, DuBois SG. Comparison of clinical features and outcomes in patients with bilateral versus unilateral adrenal neuroblastoma. J Pediatr Hematol Oncol. 2017;39(2):108–13.

    Article  PubMed  Google Scholar 

  22. Pranzatelli MR. The neurobiology of the opsoclonus-myoclonus syndrome. Clin Neuropharmacol. 1992;15(3):186–228.

    Article  CAS  PubMed  Google Scholar 

  23. Rudnick E, Khakoo Y, Antunes NL, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: clinical outcome and antineuronal antibodies-a report from the Children’s Cancer Group Study. Med Pediatr Oncol. 2001;36(6):612–22.

    Article  CAS  PubMed  Google Scholar 

  24. Antunes NL, Khakoo Y, Matthay KK, et al. Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. J Pediatr Hematol Oncol. 2000;22(4):315–20.

    Article  CAS  PubMed  Google Scholar 

  25. Mitchell WG, Davalos-Gonzalez Y, Brumm VL, et al. Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics. 2002;109(1):86–98.

    Article  PubMed  Google Scholar 

  26. Altman AJ, Baehner RL. Favorable prognosis for survival in children with coincident opso-myoclonus and neuroblastoma. Cancer. 1976;37(2):846–52.

    Article  CAS  PubMed  Google Scholar 

  27. Cooper R, Khakoo Y, Matthay KK, et al. Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children’s Cancer Group. Med Pediatr Oncol. 2001;36(6):623–9.

    Article  CAS  PubMed  Google Scholar 

  28. Hayward K, Jeremy RJ, Jenkins S, et al. Long-term neurobehavioral outcomes in children with neuroblastoma and opsoclonus-myoclonus-ataxia syndrome: relationship to MRI findings and anti-neuronal antibodies. J Pediatr. 2001;139(4):552–9.

    Article  CAS  PubMed  Google Scholar 

  29. De Grandis E, Parodi S, Conte M, et al. Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome. Neuropediatrics. 2009;40(3):103–11.

    Article  PubMed  Google Scholar 

  30. De Alarcon P, Matthay KK, London WB, et al. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc Health. 2018;2(1):25–34.

    Article  PubMed  Google Scholar 

  31. Cooney DR, Voorhess ML, Fisher JE, Brecher M, Karp MP, Jewett TC. Vasoactive intestinal peptide producing neuroblastoma. J Pediatr Surg. 1982;17(6):821–5.

    Article  CAS  PubMed  Google Scholar 

  32. El Shafie M, Samuel D, Klippel CH, Robinson MG, Cullen BJ. Intractable diarrhea in children with VIP-secreting ganglioneuroblastomas. J Pediatr Surg. 1983;18(1):34–6.

    Article  PubMed  Google Scholar 

  33. Scheibel E, Rechnitzer C, Fahrenkrug J, Hertz H. Vasoactive intestinal polypeptide (VIP) in children with neural crest tumours. Acta Paediatr Scand. 1982;71(5):721–5.

    Article  CAS  PubMed  Google Scholar 

  34. Qualman SJ, O’Dorisio MS, Fleshman DJ, Shimada H, O’Dorisio TM. Neuroblastoma. Correlation of neuropeptide expression in tumor tissue with other prognostic factors. Cancer. 1992;70(7):2005–12.

    Google Scholar 

  35. Wolff JE, Bauch HJ, Roessner A, et al. Development of hypertension in neuroblastoma during therapy: a case report. Med Pediatr Oncol. 1993;21(6):460–4.

    Article  CAS  PubMed  Google Scholar 

  36. Seefelder C, Sparks JW, Chirnomas D, Diller L, Shamberger RC. Perioperative management of a child with severe hypertension from a catecholamine secreting neuroblastoma. Paediatr Anaesth. 2005;15(7):606–10.

    Article  PubMed  Google Scholar 

  37. Shimada H, Umehara S, Monobe Y, et al. International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children’s Cancer Group. Cancer. 2001;92(9):2451–61.

    Article  CAS  PubMed  Google Scholar 

  38. Peuchmaur M, d’Amore ES, Joshi VV, et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer. 2003;98(10):2274–81.

    Google Scholar 

  39. Matthay KK, Edeline V, Lumbroso J, et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol. 2003;21(13):2486–91.

    Article  PubMed  Google Scholar 

  40. Lewington V, Lambert B, Poetschger U, et al. (123)I-mIBG scintigraphy in neuroblastoma: development of a SIOPEN semi-quantitative reporting, method by an international panel. Eur J Nucl Med Mol Imaging. 2017;44(2):234–41.

    Article  CAS  PubMed  Google Scholar 

  41. Gauguet JM, Pace-Emerson T, Grant FD, et al. Evaluation of the utility of (99m) Tc-MDP bone scintigraphy versus MIBG scintigraphy and cross-sectional imaging for staging patients with neuroblastoma. Pediatr Blood Cancer. 2017;64:11.

    Article  Google Scholar 

  42. Burchill SA, Beiske K, Shimada H, et al. Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. Cancer. 2017;123(7):1095–105.

    Article  PubMed  Google Scholar 

  43. Laug WE, Siegel SE, Shaw KN, Landing B, Baptista J, Gutenstein M. Initial urinary catecholamine metabolite concentrations and prognosis in neuroblastoma. Pediatrics. 1978;62(1):77–83.

    Article  CAS  PubMed  Google Scholar 

  44. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11(8):1466–77.

    Article  CAS  PubMed  Google Scholar 

  45. Park JR, Bagatell R, Cohn SL, et al. Revisions to the international neuroblastoma response criteria: a consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017;35(22):2580–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27(2):289–97.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Monclair T, Brodeur GM, Ambros PF, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27(2):298–303.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Brisse HJ, McCarville MB, Granata C, et al. Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology. 2011;261(1):243–57.

    Article  PubMed  Google Scholar 

  49. Breslow N, McCann B. Statistical estimation of prognosis for children with neuroblastoma. Cancer Res. 1971;31(12):2098–103.

    CAS  PubMed  Google Scholar 

  50. Pugh TJ, Morozova O, Attiyeh EF, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013;45(3):279–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Molenaar JJ, Koster J, Zwijnenburg DA, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature. 2012;483(7391):589–93.

    Article  CAS  PubMed  Google Scholar 

  52. Cheung NK, Zhang J, Lu C, et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA. 2012;307(10):1062–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Asgharzadeh S, Pique-Regi R, Sposto R, et al. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst. 2006;98(17):1193–203.

    Article  CAS  PubMed  Google Scholar 

  54. Asgharzadeh S, Salo JA, Ji L, et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol. 2012;30(28):3525–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224(4653):1121–4.

    Article  CAS  PubMed  Google Scholar 

  56. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985;313(18):1111–6.

    Article  CAS  PubMed  Google Scholar 

  57. Thompson D, Vo KT, London WB, et al. Identification of patient subgroups with markedly disparate rates of MYCN amplification in neuroblastoma: a report from the International Neuroblastoma Risk Group project. Cancer. 2016;122(6):935–45.

    Article  PubMed  Google Scholar 

  58. Shapiro DN, Valentine MB, Rowe ST, et al. Detection of N-myc gene amplification by fluorescence in situ hybridization. Diagnostic utility for neuroblastoma. Am J Pathol. 1993;142(5):1339–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  59. Ambros PF, Ambros IM, Brodeur GM, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer. 2009;100(9):1471–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Janoueix-Lerosey I, Schleiermacher G, Michels E, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol. 2009;27(7):1026–33.

    Article  PubMed  Google Scholar 

  61. Caron H, van Sluis P, de Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med. 1996;334(4):225–30.

    Article  CAS  PubMed  Google Scholar 

  62. Rubie H, Delattre O, Hartmann O, et al. Loss of chromosome 1p may have a prognostic value in localised neuroblastoma: results of the French NBL 90 Study. Neuroblastoma Study Group of the Societe Francaise d’Oncologie Pediatrique (SFOP). Eur J Cancer. 1997;33(12):1917–22.

    Article  CAS  PubMed  Google Scholar 

  63. Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999;340(25):1954–61.

    Article  CAS  PubMed  Google Scholar 

  64. Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005;353(21):2243–53.

    Article  CAS  PubMed  Google Scholar 

  65. Schleiermacher G, Janoueix-Lerosey I, Ribeiro A, et al. Accumulation of segmental alterations determines progression in neuroblastoma. J Clin Oncol. 2010;28(19):3122–30.

    Article  PubMed  Google Scholar 

  66. Schleiermacher G, Michon J, Ribeiro A, et al. Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study). Br J Cancer. 2011;105(12):1940–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Defferrari R, Mazzocco K, Ambros IM, et al. Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification. Br J Cancer. 2015;112(2):290–5.

    Article  CAS  PubMed  Google Scholar 

  68. Look AT, Hayes FA, Nitschke R, McWilliams NB, Green AA. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med. 1984;311(4):231–5.

    Article  CAS  PubMed  Google Scholar 

  69. Look AT, Hayes FA, Shuster JJ, et al. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 1991;9(4):581–91.

    Article  CAS  PubMed  Google Scholar 

  70. Baker DL, Schmidt ML, Cohn SL, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010;363(14):1313–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. George RE, London WB, Cohn SL, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 2005;23(27):6466–73.

    Article  CAS  PubMed  Google Scholar 

  72. Bagatell R, Beck-Popovic M, London WB, et al. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J Clin Oncol. 2009;27(3):365–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.

    Article  CAS  PubMed  Google Scholar 

  74. Bagatell R, McHugh K, Naranjo A, et al. Assessment of primary site response in children with high-risk neuroblastoma: an international multicenter study. J Clin Oncol. 2016;34(7):740–6.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Children’s Hospital of Philadelphia and Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

    Rochelle Bagatell

  2. Children’s Hospital Colorado and University of Colorado School of Medicine, Aurora, CO, USA

    Margaret Macy

Authors
  1. Rochelle Bagatell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Margaret Macy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rochelle Bagatell .

Editor information

Editors and Affiliations

  1. Department of Pediatrics, Children’s Hospital Los Angeles, Los Angeles, CA, USA

    Shahab Asgharzadeh

  2. Department of Neuroblastoma Genomics, German Cancer Research Center, Heidelberg, Baden-Württemberg, Germany

    Frank Westermann

Rights and permissions

Reprints and permissions

Copyright information

© 2024 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bagatell, R., Macy, M. (2024). Epidemiology, Presentation, and Evaluation. In: Asgharzadeh, S., Westermann, F. (eds) Neuroblastoma. Pediatric Oncology. Springer, Cham. https://doi.org/10.1007/978-3-031-51292-6_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-51292-6_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-51291-9

  • Online ISBN: 978-3-031-51292-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation